Prodrug approach for increasing cellular glutathione levels

Molecules

Volumn 15, Issue 3, 2010, Pages 1242-1264

  Cacciatore, Ivana ^a   Cornacchia, Catia ^a   Pinnen, Francesco ^a   Mollica, Adriano ^a   Di Stefano, Antonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Glutathione; Glutathione deficiency; Glutathione prodrugs

Indexed keywords

GLUTATHIONE; PRODRUG;

ARTICLE; CLASSIFICATION; GENERAL ASPECTS OF DISEASE; HUMAN; METABOLISM;

DISEASE; GLUTATHIONE; HUMANS; PRODRUGS;

EID: 77950343169     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15031242     Document Type: Article

References (133)

1. Meister, A. Glutathione metabolism and its selective modification. J. Biol. Chem. 1988, 263, 17205-17208.
2. Lu, S. C. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J. 1999, 13, 1169-1183.
3. Meister, A.; Anderson, M. E. Glutathione. Ann. Rev. Biochem. 1983, 52, 711-760.
4. Griffith, O. W. Biological and pharmacological regulation of mammalian glutathione synthesis. Free Rad. Biol. Med. 1999, 27, 922-925.
5. Anderson, M. E. Glutathione: An overview of biosynthesis and modulation. Chem. Biol. Interact. 1998, 111-112, 1-14.
6. Sies, H. Glutathione and its role in cellular functions. Free Radic. Biol. Med. 1999, 27, 916-921.
7. Ballatori, N.; Krance, S. M.; Notemboom, S.; Shi, S.; Tieu, K.; Hammond, C. L. Glutathione dysregulation and the etiology and progression of human diseases. Biol. Chem. 2009, 390, 191-214.
8. Kozak, E. M.; Tate, S. S. Glutathione-degrading enzymes of microvillus membranes. J. Biol. Chem. 1982, 257, 6322-6327.
9. Meister, A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal: Application in research therapy. Pharm. Therapeut. 1991, 51, 155-194.
10. Wang, W.; Ballatori, N. Endogenous glutathione conjugates: Occurrence and biological functions. Pharmacol. Rev. 1998, 50, 335-355.
11. Fang, Y. Z.; Yang, S.; Wu, G. Free radicals, antioxidants, and nutrition. Nutrition 2002, 18, 872-879.
12. Wu, G.; Fang, Y. Z.; Yang, S.; Lupton, J. R.; Turner, N. D. Glutathione metabolism and its implications for health. J. Nutr. 2004, 134, 489-492.
13. Lei, X. G. In vivo antioxidant role of glutathione peroxidase: Evidence from knockout mice. Methods Enzymol. 2002, 347, 213-225.
14. Hinchman, C. A.; Ballatori, N. Glutathione conjugation and conversion to mercapturic acids can occur a an intrahepatic process. J. Toxicol. Environ. Health 1994, 41, 387-409.
15. Ballatori, N. Glutathione mercaptides as transport forms of metals. Adv. Pharmacol. 1994, 27, 271-298.
16. Hammond, C. L.; Lee, T. K.; Ballatori, N. Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes. J. Hepatol. 2001, 34, 946-954.
17. Butterfield, D. A.; Pocernich, C. B.; Drake, J. Elevated glutathione as a therapeutic strategy in alzheimer's disease. Drug Dev. Res. 2002, 56, 428-437.
18. Barker, J. E.; Bolanos, J. P.; Land, J. M.; Clark, J. B.; Heales, S. J. Glutathione protects astrocytes from peroxynitrite-mediated mitochondrial damage: Implications for neuronal/astrocytic trafficking and neurodegeneration. Dev. Neurosci. 1996, 18, 391-396.
19. Townsend, D. M.; Tew, K. D.; Tapiero, H. The importance of glutathione in human disease. Biomed. Pharmacother. 2003, 57, 145-155.
20. Lu, S. C. Regulation of glutathione synthesis. Curr. Top. Cell. Regul. 2000, 36, 95-116.
21. Fenves, A. Z.; Kirkpatrick, H. M.; Patel, V. V.; Sweetman, L.; Emmett, M. Increased Anion Gap Metabolic Acidosis as a Result of 5-Oxoproline (Pyroglutamic Acid) : A Role for Acetaminophen. Clin. J. Am. Soc. Nephrol. 2006, 1, 441-447.
22. Njalsson, R.; Norgren, S. Physiological and pathological aspects of GSH metabolism. Acta Paediatr. 2005, 94, 132-137.
23. Ristoff, E.; Larsson, A. Inborn errors in the metabolism of glutathione. Orphanet J. Rare Dis. 2007, 2, 16-24.
24. Tsyupko, A. N.; Dudnik, L. B.; Evstigneeva, R. P.; Alessenko, A. V. Effects of reduced and oxidized glutathione on shingomyelinase activity and contents of shingomyelin and lipid peroxidation products in murine liver. Biochemistry 2001, 66, 1028-1034.
25. Franco, R.; Schoneveld, O. J.; Pappa, A.; Panayiotidis, M. I. The central role of glutathione in the phatophysiology of human diseases. Arch. Physiol. Biochem. 2007, 113, 234-258.
26. Bains, J. S.; Shaw, C. A. Neurodegenerative disorders in humans: The role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Rev. 1997, 25, 335-358.
27. Pastore, A.; Federici, G.; Bertini, E.; Piemonte, F. Analysis of Glutathione: Implication in redox and detoxification. Clin. Chim. Acta. 2003, 333, 19-39.
28. Sian, J.; Dexter, D. T.; Lees, A. J.; Daniel, S.; Agid, Y.; Javoy-Agid, F.; Jenner, P.; Marsden, C. D. Alteration in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 1994, 36, 348-355.
29. Serra, P. A.; Esposito, G.; Enrico, P.; Mura M. A.; Migheli, R.; Delogu M. R.; Miele, M.; Desole, M. S.; Grella, G.; Miele, E. Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: Potential implications to l-DOPA long-term therapy of Parkinson's disease. Br. J. Pharmacol. 2000, 130, 937-945. (Pubitemid 30389076)
30. Tofaris, G. K.; Spillantini, M. G. Alpha-synuclein dysfunction in Lewy body diseases. Mov. Disord. 2005, 20, S37-S44.
31. Chinta, S. J.; Rajagopalan, S.; Butterfield, D. A.; Andersen, J. K. In vitro and in vivo neuroprotection by γ-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson's disease. Neurosci. Lett. 2006, 40, 137-141. (Pubitemid 43766441)
32. Barath, S.; Hsu, M.; Kaur, D.; Rajagopalan, S.; Andersen, J. K. Glutathione, iron and Parkinson's disease. Biochem. Pharmacol. 2002, 40, 1037-1048. (Pubitemid 35232279)
33. Hsu, M.; Bharath, S.; Jyothi, K.; Rajagopalan, S.; Andersen, J. K. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implication for Parkinson's disease. J. Neurochem. 2005, 92, 1091-1103. (Pubitemid 40344300)
34. Rieder, P.; Dirr, A.; Goetz, M.; Sofic, E.; Youdim, M. B. H. Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann. Neurol. 1992, 32, S101-S104.
35. Albers, D. S.; Beal, M. F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural. Transm. 2000, 59, 133-154. (Pubitemid 30479414)
36. Jenner, P. Oxidative mechanism in nigral cell death in Parkinson's disease. Mov. Disord. 1998, 13, 24-34. (Pubitemid 28221476)
37. Spencer, J. P. E.; Jenner, P.; Daniel, S. E.; Lees, A. J.; Marsden, D. C.; Halliwell, B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: Possible mechanism of formation involving reactive oxygen species. J. Neurochem. 1998, 71, 2112-2122. (Pubitemid 28491568)
38. Andersen, J. K.; Mo, J. Q.; Hom D. G.; Lee, F. Y.; Harnish, P.; Hamill, R. W.; McNeill, T. H. Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons. J. Neurochem. 1996, 67, 2164-2171. (Pubitemid 26349695)
39. Lau, L. F.; Brodney, M. A. Therapeutic approaches for the treatment of Alzheimer's disease: An overview. Top. Med. Chem. 2008, 2, 1-24.
40. Gu, M.; Owen, A. D.; Toffa, S. E. K.; Cooper, J. M.; Dexter, D. T.; Jenner, P.; Marsden, C. D.; Schapira, A. H. V. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J. Neurol. Sci. 1998, 158, 24-29. (Pubitemid 28277530)
41. Liu, H.; Harrell, L. E.; Shenvi, S.; Hagen, T.; Liu, R. M. Gender differences in glutathione metabolism in Alzheimer's disease. J. Neurosci. Res. 2005, 79, 861-867.
42. Adams, J. D.; Klaidman, L. K.; Odunze, I. N.; Shen, H. C.; Miller, C. A. Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. Mol. Chem. Neurophatol. 1991, 14, 213-226.
43. Perry, T. L.; Yong, V. W.; Bergeron, C.; Hansen, S.; Jones, K. Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer's disease. Ann. Neurol. 2005, 21, 331-336.
44. Mark, R. J.; Lovell, M. A.; Markesbery, W. R.; Uchida, K.; Mattson, M. P. A role for 4-hydroxynonenal, an aldehyde product of lipid peroxidation, in disruption of iron homeostasis and neuronal death induced by amyloid β-peptide. J. Neurochem. 1997, 68, 255-264.
45. Linsdell, P.; Hanrahan, J. W. Glutathione permeability of CFTR. Am. J. Physiol. 1998, 275, C323-C326.
46. Kidd, P. M. Glutathione: Systemic protectant against oxidative and free radical damage. Altern. Med. Rev. 1997, 2, 155-176.
47. Roum, J. H.; Buhl, R.; McElvaney, N. G.; Borok, Z.; Crystal, R. G. Systemic deficiency of glutathione in cystic fibrosis. J. Appl. Physiol. 1993, 75, 2419-2424.
48. Hudson, V. Rethinking cystic fibrosis pathology: the critical role ob abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radical. Biol. Med. 2001, 30, 1440-1461.
49. Brown, R. K.; ScBurney, A.; Lunec, J.; Kelly, F. J. Oxidative damage to DNA in patients with cystic fibrosis. Free Radical. Biol. Med. 1995, 234, 137-146.
50. Brown, R. K.; Wyatt, H.; Price, J. F.; Kelly, F. J. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. Eur. Respir. J. 1996, 9, 334-339.
51. Lomaestro, B. M.; Malone, M. Glutathione in health and disease: Pharmacotherapeutic issues. Annals Pharmacother. 1995, 29, 1263-1273.
52. Beck, M. A. The influence of antioxidant nutrients on viral infection. Nutr. Rev. 1998, 127, S140-S146.
53. Peterhans, E. Oxidants and antioxidants in viral diseases: Disease mechanisms and metabolic regulation. J. Nutr. 1997, 127, S962-S965.
54. Fraternale, A.; Paoletti, M. F.; Casabianca, A.; Nencioni, L.; Garaci, E.; Palamara, A. T.; Magnani, M. GSH and analogs in antiviral therapy. Mol. Aspects Med. 2009, 30, 99-110.
55. Cai, J.; Chen, Y.; Seth, S.; Furukawa, S.; Compans, R. W.; Jones, D. P. Inhibition of influenza infection by glutathione. Free Radical. Biol. Med. 2003, 34, 928-936.
56. Buhl, R.; Jaffe, H. A.; Holroyd, K. J.; Wells, F. B.; Mastrangeli, A.; Saltini, C. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989, 2, 1294-1298.
57. De Quay, B.; Maliverni, R.; Lauterburg, B. H. Glutathione depletion in HIV-infected patients: Role of cysteine deficiency and effect of oral N-acetylcysteine. Aids 1992, 6, 815-819.
58. Lopez Galera, R. M.; Juarez Gimenez, J. C.; Montoro Ronsano, J. B.; Segura Cardona, R. M.; Arbos Via, M. A.; Altisent Roca, C.; Tusell Puigbert, J. M. Glutathione and cysteine in HIV-infected hemophiliacs. Clin. Chim. Acta 1996, 254, 63-72.
59. Maher, P. The effects of stress and aging on glutathione metabolism. Ageing Res. Rev. 2005, 4, 288-314.
60. Yoshikawa, M.; Hirai, S. Lipid peroxide formation in the brain of aging rats. J. Gerontol. 1967, 22, 162-165.
61. Liu, H.; Wang, H.; Shenvi, S.; Hagen, T. M.; Lir, R. M. Glutathione metabolism during aging and in Alzheimer's disease. Ann. NY Acad. Sci. 2004, 1019, 346-349.
62. Harding, J. J. Free radical and protein-bound glutathione in normal and cataractous human lenses. Biochem. J. 1970, 117, 957-960.
63. Samiec, P. S.; Drews-Botsch, C.; Flagg, E. W.; Kurtz, J. C.; Sternberg, P.; Reed, R. L.; Jones, D. P. Glutathione in human plasma: Decline in association with aging, age-related macular degeneration, and diabetes. Free Radic. Biol. Med. 1998, 24, 699-704.
64. Wendel, A.; Cikryt, P. The level and half-life of glutathione in human plasma. FEBS Lett. 1980, 120, 209-211.
65. Anderson, M. E.; Luo, J. L. Glutathione therapy: From prodrugs to genes. Semin. Liver Dis. 1998, 18, 415-424.
66. Richman, P. G.; Meister, A. Regulation of γ-glutamylcysteine synthetase by nonallosteric feedback inhibition by glutathione. J. Biol. Chem. 1975, 250, 1422-1426.
67. Anderson, M. E.; Powrie, F.; Puri, R. N.; Meister, A. Glutathione monoethyl ester: Preparation, uptake by tissues, and conversion to glutathione. Arch. Biochem. Biophys. 1985, 239, 538-548.
68. Anderson, M. E.; Nilsson, M.; Sims, N. R. Glutathione monoethyl ester prevent mitochondrial glutathione depletion during focal cerebral ischemia. Neurochem. Int. 2004, 44, 153-159.
69. Fernandez-Checa, J. C.; Garcia-Ruiz, C.; Ookhtens, M.; Kaplowitz, N. Impaired uptake of glutathione by hepatic mitochondria from chronic ethanol-fed rats. Tracer kinetic studies in vitro and in vivo and susceptibility to oxidant stress. J. Clin. Invest. 1991, 87, 397-405.
70. Puri, R. N.; Meister A. Transport of glutathione, as γ- glutamylcysteinylglycyl ester, into liver and kidney. Proc. Natl. Acad. Sci. 1983, 80, 5258-5260.
71. Tsan, M. F.; White, J. E.; Rosano, C. L. Modulation of endothelial GSH concentrations: Effect of exogenous GSH and GSH monoethyl ester. J. Appl. Physiol. 1989, 66, 1029-1034.
72. Wellner, V. P.; Anderson, M. E.; Puri, R. N.; Jensen, G. L.; Meister A. Radioprotection by glutathione ester transport of glutathione ester into human lymphoid cells and fibroblasts. Proc. Natl. Acad. Sci. USA 1984, 81, 4732-4735.
73. Zeevalk, G. D.; Manzino, L.; Sonsalla, P. K.; Bernard, L. P. Characterization of intracellular elevation of glutathione with glutathione monoethyl ester and GSH in brain and neuronal cultures: Relevance to Parkinson's disease. Exp. Neurol. 2007, 203, 512-520.
74. Chen, T. S.; Richie, J. P.; Nagasawa, H. T.; Lang, C. A. Glutathione monoethyl ester protects against glutathione deficiencies due to aging and acetaminophen in mice. Mech. Ageing Dev. 2000, 120, 127-139.
75. Uedono, Y.; Takeyama, N.; Yamagami, K.; Tanaka, T. Lipopolysaccharide- mediated hepatic glutathione depletion and progressive mitochondrial damage in mice: protective effect of glutathione monoethyl ester. J. Surg. Res. 1997, 70, 49-54.
76. Jennische, E. Possible influence of glutathione on postischemic liver injury. Acta Pathol. Microbiol. Immunol. Scand. 1984, 92, 55-64.
77. Grattagliano, I.; Vendemiale, G.; Lauterburg, B. H. Reperfusion iniury of the liver: Role of mitochondria and protection by glutathione ester. J. Surg. Res. 1999, 86, 2-8.
78. Anderson, M. F.; Nilsson, M.; Eriksson, P. S.; Sims, N. R. Glutathione monoethyl ester provides neuroprotection in a rat model of stroke. Neurosci. Lett. 2004, 354, 163-165.
79. Levy, E. J.; Anderson, M. E.; Meister, A. Transport of glutathione diethyl ester into human cells. Proc. Natl. Acad. Sci. USA 1993, 90, 9171-9175.
80. Anderson, M. E. Glutathione and glutathione delivery compounds. Adv. Pharmacol. 1997, 38, 65-78.
81. 1cells by reduced glutathione and its mono-and diethyl ester derivatives. Biochem. Pharmacol. 1195, 49, 1475-1482.
82. Yamaguchi, N.; Yajima, N.; Ishida, M.; Shimada, T.; Hiraishi, H. Protection of cultured gastric cells against tert-butyl hydroperoxide by glutathione isopropyl ester. Eur. J. Pharmacol. 1998, 351, 363-369.
83. Gotoh, O.; Yamamoto, M.; TamuraA.; Sano, K. effect of YM737, a new glutathione analog, on ischemic brain edema. Acta Neurochir. 1994, 60, 318-320.
84. Shibata, S.; Tominaga, K.; Watanabe, S. Glutathione protects against hypoxic/hypoglycaemic decreases in 2-deoxyglucose uptake and presynaptic spikes in hippocampal slices. Eur. J. Pharmacol. 1995, 273, 191-195.
85. Rizzoli, V.; Schiappelli, P.; Moretto, C.; Galzigna, L. S-acetyl and S-phenylacethyl-glutathione in rat brain tissue. Eur. J. Lab. Med. 1995, 3, 11-13.
86. Vogel, J. U.; Cinatl, J.; Dauletbaev, N.; Buxbaum, S.; Treusch, G.; Cinatl, J.; Gerein, V.; Doerr, H. W. Effects of S-acetylglutathione in cell and animal model of herpes simplex virus type 1 infection. Med. Microbio. Immunol. 2005, 194, 55-59.
87. Fraternale, A.; Paoletti, M. F.; Casabianca, A.; Orlandi, C.; Schiavano, G. F.; Chiarantini, L.; Clayette, P.; Oiry, J.; Vogel, J. U.; Cinatl, J.; Magnani, M. Inhibition of murine AIDS by pro-glutathione (GSH) molecules. Antivir. Res. 2008, 77, 120-127.
88. Berkeley, L. I.; Cohen, J. F.; Crankshaw, D. L.; Shirota, F. N.; Nagasawa, H. T. Hepatoprotection by-L-cysteine-glutathione mixed disulfide, a sulfhydryl-modified prodrug of glutathione. J. Biochem. Mol. Toxicol. 2003, 17, 95-97.
89. Phimister, A. J.; Nagasawa, H. T.; Buckpitt, A. R.; Plopper, C. G. Prevention of naphthalene-induced pulmonary toxicity by glutathione prodrugs: Role for glutathione depletion in adduct formation and cell injury. J. Biochem. Mol. Toxicol. 2005, 19, 42-51.
90. Griffith, O. W.; Meister, A. Glutathione: interorgan translocation, turnover, and metabolism. Proc. Natl. Acad. Sci. USA 1979, 76, 5606-5610.
91. Meister, A. Methods for the selective modification of glutathione metabolism and study of glutathione transport. Methods Enzymol. 1985, 113, 571-585.
92. Griffith, O. W. Biological and pharmacological regulation of mammalianglutathione synthesis. Free Radic. Biol. Med. 1999, 27, 922-935.
93. Baker, D. A.; McFarland, K.; Lake, R.; Shen, H.; Tang, X. C.; Toda, S.; Kalivas, P. W. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat. Neurosci. 2003, 6, 743-749.
94. De Vries, N.; De Flora, S. N-Acetyl-l-Cysteine. J. Cell. Biochem. 1993, 53, 270-277.
95. Millar, A.; Pavia, D.; Agnew, J. E.; Lopez-Vidriero, M. T.; Lauque, D.; Clarke, W. Effect of oral N-acetylcysteine on mucus clearance. J. Did. Chest. 1985, 79, 262-266.
96. Banaclocha, M. M. Therapeutic potential of N-acetylcysteine in age-related mitochondrial neurodegenerative diseases. Med. Hypotheses 2001, 56, 472-477.
97. Atkuri, K. R.; Mantovani, J. J.; Herzenberg, L. A.; Herzenberg L. A. N-Acetylcysteine: A safe antidote for cysteine/glutathione deficiency. Curr. Opin. Pharmacol. 2007, 7, 1-5.
98. Kelly, G. S. Clinical applications of N-acetylcysteine. Altern. Med. Rev. 1998, 3, 114-127.
99. Ates, B.; Abraham, L.; Ercal, N. Antioxidant and free radical scavenging properties of N-acetylcysteine amide (NACA) and comparison with N-acetylcysteine (NAC). Free Radic. Res. 2008, 42, 372-377.
100. Kahns, A. H.; Bundgaard, H. Prodrugs as drug delivery systems. 107. Synthesis and chemical and enzymatic hydrolysis kinetics of various mono-and diester prodrugs of N-acetylcysteine. Int. J. Pharm. 1990, 62, 193.
101. Grinberg, L.; Fibach, E.; Amer, J.; Atlas, D. N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress. Free Radic. Biol. Med. 2005, 38, 136-145.
102. Santangelo, F. Intracellular thiol concentration modulating inflammatory response: Influence on the regulation of cell functions through cysteine prodrug approach. Curr. Med. Chem. 2003, 10, 2599-2610. (Pubitemid 37456029)
103. Jones, M. G.; Hughes, J.; Tregova, A.; Milne, J.; Tomsett, A. B.; Collin, H. A. Biosynthesis of the flavour precursors of onion and garlic. J. Exp. Bot. 2004, 55, 1903-1918. (Pubitemid 39123323)
104. Hsu, C. C.; Yen, H. F.; Yin, M. C.; Tsai, C. M. Five cysteine-containing compounds delay diabetic deterioration in Balb/cA mice, J. Nutr. 2004, 134, 3250-3256.
105. Hsu, C. C.; Lin, C. C.; Liao, T. S.; Yin, M. C. Protective effect of S-allyl cysteine and S-propyl cysteine on acetaminophen-induced hepatotoxicity in mice. Food Chem. Toxicol. 2006, 44, 393-397. (Pubitemid 41779440)
106. Chen, C. M.; Yin, M. C.; Hsu, C. C.; Liu, T. C. Antioxidative and anti-inflammatory effects of four cysteine-containing agents in striatum of MPTP-treated mice. Nutrition 2007, 23, 589-597.
107. Schubert, M. P. Compounds of thiol acids with aldehydes. J. Biol. Chem. 1936, 114, 341-350.
108. Nagasawa, H. T.; Goon, D. J. W.; Muldoon, W. P.; Zera, R. T. 2-Substituted thiazolidine-4 (R) - carboxylic acids as prodrugs of L-cysteine. Protection of mice against acetaminophen hepatotoxicity. J. Med. Chem. 1984, 27, 591-596.
109. Porta, P.; Aebi, S.; Summer, K.; Lauterburg, B. H. L-2-oxothiazolidine-4- carboxylic acid, a cysteine prodrug: Pharmacokinetics and effects on thiols in plasma and lymphocytes in human. J. Pharmacol. Exp. Ther. 1991, 257, 331-334.
110. Roberts, J. C.; Nagasawa, H. T.; Zera, R. T.; Fricke, R. F.; Goon, D. J. Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl) - and 2-(polyacetoxyalkyl) thiazolidine-4 (R) -carboxylic acids. J. Med. Chem. 1987, 30, 1891-1896.
111. Li, J.; Wang, H.; Stoner, G. D.; Bray, T. M. Dietary supplementation with cysteine prodrugs selectively restores tissue glutathione levels and redox status in protein-malnourished mice. J. Nutr. Biochem. 2002, 13, 625-633. (Pubitemid 35246553)
112. Yokota, N.; Kuga, Y.; Kanazawa, T.; Morishita, M.; Tanida, K.; Itou, K. Ten years results of bucillamine in the treatment of rheumatoid arthritis. Mod. Reumatol. 2007, 17, 33-36. (Pubitemid 46758767)
113. Horwitz, L. D. Bucillamine: a potent thiol donor with multiple clinical applications. Cardiovasc. Drug Rev. 2003, 21, 77-90.
114. Amersi, F.; Nelson, S. K.; Shen, X. D.; Kato, H.; Melinek, J.; Kupiec-Weglinski, J. W.; Horwitz, L. D.; Busuttil, R. W.; Horwitz, M. A. Bucillamine, a thiol antioxidant, prevents transplantation-associated reperfusion injury. Proc. Natl. Acad. Sci. USA 2002, 99, 8915-8920.
115. Singh, G.; Sharma, P. D. Mutual prodrugs: A recent trend in prodrug design. Indian J. Pharm. Sci. 1994, 56, 69-79. (Pubitemid 24213983)
116. Lau, W. M.; White, A. W.; Gallagher, S. J.; Donaldson, M.; McNaughton, G.; Heard, C. M. Scope and limitations of the codrug approach to topical drug delivery. Curr. Pharm. Des. 2008, 14, 794-802.
117. Rosini, M.; Andrisano, V.; Bartolini, M.; Bolognesi, M. L.; Hrelia P.; Minarini, A.; Tarozzi, A.; Melchiorre, C. Rational approach to discover multipotent anti-Alzheimer drugs. J. Med. Chem. 2005, 48, 360-363. (Pubitemid 40139781)
118. Pinnen, F.; Cacciatore, I.; Cornacchia, C.; Sozio, P.; Iannitelli, A.; Costa, M.; Pecci, L.; Nasuti, C.; Cantalamessa, F.; Di Stefano, A. Synthesis and study of L-Dopa-glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties. J. Med. Chem. 2007, 50, 2506-2515. (Pubitemid 46799262)
119. More, S. S.; Vince, R. Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs. J. Med. Chem. 2008, 51, 4581-4588.
120. Vince, R.; Brownell, J.; Akella, L. B. Synthesis and activity of γ-(l-γ-azaglutamyl) -S-(p-bromobenzyl) -l-cysteinylglycine: A metabolically stable inhibitor of glyoxalase I. Bioorg. Med. Chem. Lett. 1999, 9, 853-856.
121. More, S. S.; Vince, R. A Metabolically stable tight-binding transition-state inhibitor of glyoxalase-I. Bioorg. Med. Chem. Lett. 2006, 16, 6039-6042.
122. Bickel, U.; Kang, Y. S.; Pardridge, W. M. In vivo cleavability of a disulfide-based chimeric opioid peptide in rat brain. Bioconjugate Chem. 1995, 6, 211-218.
123. Ehrlich, K.; Viirlaid, S.; Mahlapuu, R.; Saar, K.; Kullisaar, T.; Zilmer, M.; Langel, U.; Soomets, U. Design, synthesis and properties of novel powerful antioxidants, glutathione analogues. Free Radic. Res. 2007, 41, 779-787.
124. Kals, J.; Starkopf, J.; Zilmer, M.; Pruler, T.; Pulges, K.; Hallaste, M.; Kals, M.; Pulges, A.; Soomets, U. Antioxidant UPF1 attenuates myocardial stunning in isolated rat hearts Int. J. Cardiol. 2008, 125, 133-135.
125. Pileblad, E.; Magnusson, T. Increase in rat brain glutathione following intracerebroventricular administration of gamma-glutamylcysteine. Biochem. Pharmacol. 1992, 44, 895-903.
126. Drake, J.; Kanski, J.; Varadarajan, S.; Tsoras, M.; Butterfield, D. A. Elevation of brain glutathione by γ-glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress. J. Neurosci. Res. 2002, 68, 776-784.
127. Nishida, K.; Ohta, Y.; Ito, M.; Nagamura, Y.; Kitahara, S.; Fujii, K.; Ishiguro, I. Conversion of γ-glutamylcysteinylethyl ester to glutathione in rat hepatocytes. Biochim. Biophys. Acta 1996, 1313, 47-53.
128. Kobayashi, H.; Kurokawa, T.; Kitahara, S.; Nonami, T.; Harada, A.; Nakao, A.; Sugiyama, S.; Ozawa, T.; Takagi, H. The effects of gamma-glutamylcysteine ethyl ester, a prodrug of glutathione, on ischemia-reperfusion-induced liver injury in rats. Transplantation 1992, 54, 414-418.
129. Ozaki, M.; Ozasa, H.; Fuchinoue, S.; Teraoka, S.; Ota, K. Protective effects of glycine and esterified γ-glutamylcysteine on ischemia/reoxygenation injury of rat liver. Transplantation 1994, 58, 753-755.
130. Nishinaka, Y.; Kitahara, S.; Sugiyama, S.; Yokota, M.; Saito, H.; Ozawa, T. The cardioprotective effect of γ-glutamylcysteine ethyl ester during coronary reperfusion in canine hearts. Br. J. Pharmacol. 1991, 104, 805-810.
131. Hoshida, S.; Kuzuya, T.; Yamashita, N.; Nishida, M.; Kitahara, S.; Hori, M.; Kamada, T.; Tada, M. γ-Glutamylcysteine ethyl ester for myocardial protection in dogs during ischemia and reperfusion. J. Am. Coll. Cardiol. 1994, 24, 1391-1397.
132. Nishida, K.; Ohta, Y.; Ishiguro, I. Preventive effect of γ-glutamylcysteinylethyl ester on carbon tetrachloride-induced hepatic triglyceride accumulation in mice. Toxicol. Lett. 1998, 95, 141-146.
133. Okamoto, T.; Mizuta, K.; Takahashi, T.; Kishi, T.; Kitahara, S.; Komori, S.; Hashimoto, K.; Goshima, K. Protective effect of γ- glutamylcysteinylethyl ester on dysfunction of the selenium-deficient rat heart. Biochem. Pharmacol. 1999, 57, 955-963.